Supply Chain Intelligence

Zentalis Pharmaceuticals, Inc. Supply Chain

ZNTL supply chain intelligence for Zentalis Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ZNTL ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
5Customers
1Debt Items
20Related Chains

Zentalis Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
APRE Aprea Therapeutics, Inc. 72% ates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. We require that our CMOs produce active drug substance and finis…
APRE Aprea Therapeutics, Inc. 72% Reciprocal relationship from APRE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from APRE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from APRE g…
IMNM Immunome, Inc. 72% Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in co…

Zentalis Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
PFE Pfizer Inc. 90% In April 2022, we entered into a development agreement with Pfizer to collaborate to advance the clinical development of azenosertib
PFE Pfizer Inc. 90% Reciprocal relationship from PFE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from PFE grap…
GSK GSK plc 85% In April 2021, we entered into a clinical trial collaboration and supply agreement with GSK under which we have evaluated the combination of azenosertib
GSK GSK plc 85% Reciprocal relationship from GSK graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from GSK graph: Reciprocal relationship from ZNTL graph: In April 2021, we entered into a clin…
IMNM Immunome, Inc. 72% Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial compe…

Zentalis Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZNTL-DEBT Debt stack $34.6M 90% Market cache reports total debt of $34.6M.

Zentalis Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zentalis Pharmaceuticals, Inc..

Zentalis Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
ZNTL-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 105 tracked holders.

Zentalis Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CTNM Contineum Therapeutics, Inc. 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 2
IMNM Immunome, Inc. 100.00 1 ['customer', 'supplier']
BCAX Bicara Therapeutics Inc. 100.00 2
SMMT Summit Therapeutics Inc. 100.00 2
ARVN Arvinas, Inc. 100.00 2
PCVX Vaxcyte, Inc. 100.00 2
APRE Aprea Therapeutics, Inc. 100.00 1 ['supplier']
LEGN Legend Biotech Corporation 100.00 2
LIXT Lixte Biotechnology Holdings, Inc. 100.00 2
DEO Diageo plc 100.00 2
PFE Pfizer Inc. 60.75 1 ['customer']
PFIZER PFIZER 60.75 1 ['receiving']
GSK GSK plc 54.19 1 ['customer']
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
HLN Haleon plc 50.00 2
SDGR Schrödinger, Inc. 50.00 2
HBIO Harvard Bioscience, Inc. 50.00 2
INVA Innoviva, Inc. 50.00 2
ORANY ORANGE 50.00 2
View ZNTL supply chain intel →

Explore the full interactive supply chain map for Zentalis Pharmaceuticals, Inc..

Open ZNTL supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map